A STERILE, READY-TO-USE INJECTABLE FLUOROQUINOLONE TO TREAT AND CONTROL BOVINE RESPIRATORY DISEASE (BRD)
Mannheimia haemolytica
Pasteurella multocida
Histophilus somni
Mycoplasma bovis
- FDA-approved bioequivalent to Baytril 100®
- Cost-effective BRD treatment + control
- Approved for single-dose and multi-day treatment and control
A STERILE, READY-TO-USE INJECTABLE FLUOROQUINOLONE TO TREAT AND CONTROL SWINE RESPIRATORY DISEASE (SRD)
Actinobacillus pleuropneumoniae
Pasteurella multocida
Haemophilus parasuis
Streptococcus suis
Bordetella bronchiseptica
Mycoplasma hyopneumoniae
- FDA-approved bioequivalent to Baytril 100®
- Cost-effective SRD treatment + control
- Approved for colibacillosis control in weaned pigs
Important Safety Information
- Individuals with a history of hypersensitivity to quinolones should avoid this product.
- The effects of enrofloxacin on cattle or swine reproductive performance, pregnancy, and lactation have not been adequately determined.
- The long-term effects on articular joint cartilage have not been determined in swine above market weight.
- Subcutaneous injection in cattle and swine, or intramuscular injection in swine, can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.
- Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures. Quinolone-class drugs have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species.